Cognition Therapeutics Inc (CGTX) Stock Price, Quote & News

Company Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mi...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 481 2210

Website: www.cogrx.com

Address:

2500 Westchester Ave., Purchase, United States

Dmsrz8 May. 13 at 12:36 PM

$CGTX no, not with just 6k shares traded. That’s not financial terrorists

0 · Reply

Aimforsuccess May. 13 at 11:34 AM

$CGTX Looks like the financial terrorists are still trashing the stock In the premarket. Nothing but a criminal cartel aided by the SEC in my opinion.

0 · Reply

SharkLips May. 12 at 7:17 PM

$CGTX LETS GO LISA! STOP PLAYIN!

0 · Reply

Willy_Nilly May. 12 at 4:52 PM

$CGTX FDA understanda: DLB psychosis is severely underserved, caregivers are desperate for safer options, current treatments are limited or problematic, and neurodegenerative disease is a major public-health priority. I think the FDA is generally motivated to facilitate development of promising therapies in areas of high unmet need. Optimistic that they will provide a clear path fwd to determine the real benefit of the drug.. and BP will be watching and listening closely. A positive outcome in discussion will kick the door wide open to partnership and funding in a huge way.

0 · Reply

Wallstreetpenny May. 12 at 2:00 PM

$CGTX Going to be BOGO soon!

2 · Reply

Aimforsuccess May. 12 at 1:59 PM

$CGTX Same financial terrorists trying to walk it down.

0 · Reply

FitzCatalyst May. 11 at 7:46 PM

$CGTX awful

1 · Reply

SharkLips May. 11 at 4:58 PM

$CGTX well alrighty then 😉

1 · Reply

Aimforsuccess May. 11 at 4:02 PM

$CGTX Financial terrorism in my opinion from the shorts, helped by the market makers?

1 · Reply

SharkLips May. 11 at 3:02 PM

$CGTX new week, great start! smh

0 · Reply

Cognition Therapeutics reports Q1 EPS (5c), consensus (7c)

May 7, 2026, 4:15 PM EDT - 5 days ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update

Apr 13, 2026, 3:00 PM EDT - 4 weeks ago

Cognition Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 7:30 AM EDT - 5 weeks ago

Cognition Therapeutics to Present at Needham Virtual Healthcare Conference

Mar 31, 2026, 4:30 PM EDT - 6 weeks ago

Cognition Therapeutics CEO Issues Letter to Shareholders

Mar 26, 2026, 8:30 AM EDT - 6 weeks ago

Cognition Therapeutics Earnings Call Transcript: Q4 2025

Mar 26, 2026, 7:30 AM EDT - 6 weeks ago

Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

Mar 23, 2026, 7:30 AM EDT - 7 weeks ago

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

2026-03-17T11:45:37.000Z - 2 months ago

Cognition Therapeutics’ zervimesine shows eficacy in dementia trial

Mar 17, 2026, 7:30 AM EDT - 2 months ago

Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

2026-03-02T12:42:07.000Z - 2 months ago

Cognition Therapeutics announces plans to advance development of zervimesine

Mar 2, 2026, 7:30 AM EST - 2 months ago

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis

2026-02-05T12:35:13.000Z - 3 months ago

Cognition Therapeutics extends duration of EAP for zervimesine

Feb 5, 2026, 7:30 AM EST - 3 months ago

Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

2026-01-27T12:36:53.000Z - 3 months ago

Cognition Therapeutics completes Type C meeting with FDA for zervimesine

Jan 27, 2026, 7:30 AM EST - 3 months ago

Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies

2026-01-06T12:41:42.000Z - 4 months ago

Cognition publishes Phase 2 results on Zervimesine

Jan 6, 2026, 7:30 AM EST - 4 months ago

Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies

2025-12-18T21:15:25.000Z - 5 months ago

Cognition Therapeutics files $300M mixed securities shelf

Dec 3, 2025, 4:30 PM EST - 5 months ago

Cognition Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-03T12:35:14.000Z - 5 months ago

Cognition reaches full enrollment in expanded access program for CT1812

2025-12-01T12:40:30.000Z - 5 months ago

Cognition Therapeutics presents Phase 3 plan for zervimesine in Alzheimer’s

Dec 1, 2025, 7:30 AM EST - 5 months ago

Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference

2025-11-21T13:05:09.000Z - 6 months ago

Cognition Therapeutics price target raisd to $3 from $2 at B. Riley

Nov 20, 2025, 4:01 PM EST - 6 months ago

Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

2025-11-13T12:40:48.000Z - 6 months ago

Cognition Therapeutics completes enrollment in Phase 2 study of Zervimesine

Nov 13, 2025, 7:36 AM EST - 6 months ago

Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer's Disease

2025-11-06T12:41:38.000Z - 6 months ago

Cognition Therapeutics reports Q3 EPS (6c), consensus (9c)

Nov 6, 2025, 7:30 AM EST - 6 months ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

2025-09-03T11:35:11.000Z - 9 months ago

Cognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment

Sep 3, 2025, 7:30 AM EDT - 9 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target

Sep 2, 2025, 4:00 PM EDT - 9 months ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

2025-08-28T03:45:19.000Z - 9 months ago

Cognition Therapeutics announces $30M registered direct offering of common stock

Aug 27, 2025, 8:53 PM EDT - 9 months ago

Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

2025-08-26T20:05:36.000Z - 9 months ago

Cognition Therapeutics regains compliance with Nasdaq

Aug 26, 2025, 4:00 PM EDT - 9 months ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

2025-08-12T21:05:20.000Z - 9 months ago

Cognition Therapeutics confirms aligment with FDA on path for zervimesine

Aug 12, 2025, 4:00 PM EDT - 9 months ago

Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer's Disease

2025-08-07T20:10:27.000Z - 9 months ago

Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)

2025-07-29T11:40:51.000Z - 10 months ago

Cognition Therapeutics presents data at AAIC on CT1812 in dementia

Jul 29, 2025, 7:30 AM EDT - 10 months ago

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer's Disease

2025-07-21T11:45:26.000Z - 10 months ago

Cognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study

Jul 21, 2025, 7:30 AM EDT - 10 months ago

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine's Protection of Neurons and Synapses in Alzheimer's Disease

2025-07-16T11:36:22.000Z - 10 months ago

Cognition Therapeutics ot present data from zervimesine Phase 2 study

Jul 16, 2025, 7:30 AM EDT - 10 months ago

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

Jul 10, 2025, 7:30 AM EDT - 10 months ago

Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease

Jul 1, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target

Jun 25, 2025, 7:30 AM EDT - 11 months ago

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)

Jun 3, 2025, 7:30 AM EDT - 1 year ago

Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

May 28, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies

May 9, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

May 7, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer's Disease Processes

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cognition Therapeutics Transcript: Life Sciences Investor Forum

Mar 12, 2025, 4:05 PM EDT - 1 year ago

Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

Feb 27, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

Feb 25, 2025, 7:30 AM EST - 1 year ago

Cognition Therapeutics' VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

Jan 30, 2025, 7:30 AM EST - 1 year ago

Cognition's Positive Phase 2 ‘SHIMMER' Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

Jan 8, 2025, 4:14 PM EST - 1 year ago

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Dec 18, 2024, 8:00 AM EST - 1 year ago

Cognition Therapeutics Transcript: Study Result

Dec 18, 2024, 7:22 AM EST - 1 year ago

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Nov 26, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

Nov 25, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population

Nov 14, 2024, 11:00 AM EST - 1 year ago

Cognition Therapeutics Transcript: Life Sciences Investor Forum

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Nov 12, 2024, 7:30 AM EST - 1 year ago

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Oct 31, 2024, 4:15 PM EDT - 1 year ago

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Cognition Therapeutics Transcript: Study Update

Oct 29, 2024, 12:55 PM EDT - 1 year ago

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Analyses from Cognition's Positive Phase 2 ‘SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Oct 2, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

Oct 1, 2024, 7:30 AM EDT - 1 year ago

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Dmsrz8 May. 13 at 12:36 PM

$CGTX no, not with just 6k shares traded. That’s not financial terrorists

0 · Reply

Aimforsuccess May. 13 at 11:34 AM

$CGTX Looks like the financial terrorists are still trashing the stock In the premarket. Nothing but a criminal cartel aided by the SEC in my opinion.

0 · Reply

SharkLips May. 12 at 7:17 PM

$CGTX LETS GO LISA! STOP PLAYIN!

0 · Reply

Willy_Nilly May. 12 at 4:52 PM

0 · Reply

Wallstreetpenny May. 12 at 2:00 PM

$CGTX Going to be BOGO soon!

2 · Reply

Aimforsuccess May. 12 at 1:59 PM

$CGTX Same financial terrorists trying to walk it down.

0 · Reply

FitzCatalyst May. 11 at 7:46 PM

$CGTX awful

1 · Reply

SharkLips May. 11 at 4:58 PM

$CGTX well alrighty then 😉

1 · Reply

Aimforsuccess May. 11 at 4:02 PM

$CGTX Financial terrorism in my opinion from the shorts, helped by the market makers?

1 · Reply

SharkLips May. 11 at 3:02 PM

$CGTX new week, great start! smh

0 · Reply

Wallstreetpenny May. 11 at 12:42 PM

$CGTX Let’s start that march upward!

0 · Reply

BarryLong28 May. 11 at 2:22 AM

$CGTX

0 · Reply

Tyler66 May. 9 at 11:56 PM

$CGTX Bottom line: This is good incremental news that keeps momentum on a promising program in an area of high unmet need. Worth watching the outcome of the May 20 meeting (minutes likely in June) and any follow-on updates. If you’re invested or considering it, this reinforces the bullish case on zervimesine’s potential, but manage risk as with any clinical biotech. Not “moonshot today” but clearly positive

0 · Reply

Tyler66 May. 9 at 11:54 PM

$CGTX The FDA meeting on May 20, 2026 (very soon) with the Division of Psychiatry is specifically to discuss plans for a registration study. This builds on prior productive Type C/end-of-Phase 2 meetings. Positive alignment here could de-risk the path forward and support a faster/more focused development program. • Financials are solid for a micro-cap biotech: Cash ~$31M + $25.6M in NIH grant funds → runway into Q2 2027. Q1 net loss narrowed significantly (lower R&D spend as trials wind down/optimize). No immediate dilution pressure.

0 · Reply

Earlyinv May. 9 at 5:32 PM

$CGTX. It’s an hour long, but interesting listen. https://podcasts.apple.com/us/podcast/freakonomics-radio/id354668519?i=1000761903283

0 · Reply

Joeeeeeeeeeeeee May. 9 at 12:50 AM

$CGTX Makary

0 · Reply

FitzCatalyst May. 8 at 8:01 PM

$CGTX our time is coming.

0 · Reply

Rjcamel2355 May. 8 at 3:21 PM

$CGTX It is good to see the company back on a monthly-ish PR schedule. The big lapses in PR last year were kind of a downer. I understand if there is no news, what's to say, but again just nice to see.

0 · Reply

SharkLips May. 8 at 2:27 PM

$CGTX buyers? buyers?

1 · Reply

FitzCatalyst May. 8 at 2:18 PM

$CGTX should start getting traction with fda meeting 5/20 confirmed

0 · Reply

Rjcamel2355 May. 8 at 1:19 PM

$CGTX Gonna add some more.

2 · Reply

Wallstreetpenny May. 8 at 1:16 PM

$CGTX Good grief we need buyers!

0 · Reply

Market Cap	105.44M
Revenue (ttm)	0.00
Net Income (ttm)	-23.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	678,600
Avg Vol	1,188,214
Day's Range	N/A - N/A
Shares Out	89.35M
Stochastic %K	23%
Beta	1.81
Analysts	Strong Sell
Price Target	$3.50